Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS01ADC with HAIP and Systemic Therapy in Liver Metastases
NCT05286814Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of NHS-IL-12 in colorectal cancer (CRC), cholangiocarcinoma (CCA) and adrenocortical carcinoma (ACC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Oct 2022; status: recruiting.
02
Drugs
NHS-IL-12
03
Conditions
colorectal cancer (CRC)cholangiocarcinoma (CCA)adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT05286814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286814.